More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a ‘near certainty’

While Sarepta has three antisense oligonucleotide therapies approved — albeit not without controversy — for Duchenne muscular dystrophy, it has been working on a long-term treatment in the form of a gene therapy. After posting positive results for its Roche-partnered gene therapy, dubbed SRP-9001, earlier this month, the Cambridge, MA-based…

Click here to view original post